

## Clinical Policy: Ferriscan R2-MRI

Reference Number: CP.MP.53

Last Review Date: 10/20

[Coding Implications](#)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

### Description

FerriScan R2-MRI is a magnetic resonance imaging (MRI) -based solution for measuring liver iron concentration (LIC) in patients with iron overload.

### Policy/Criteria

- I. It is the policy of Health Plans affiliated with Centene Corporation<sup>®</sup> that the FerriScan<sup>®</sup> R2-MRI is **medically necessary** for the measurement of liver iron concentration in suspected cases of iron overload due to the following conditions:
  - A. Hereditary hemochromatosis;
  - B. Iron-loading anemias with or without multiple transfusions:
    - 1. Thalassemia major or thalassemia intermedia;
    - 2. Sideroblastic anemia;
    - 3. Chronic hemolytic anemias (e.g., sickle cell disease);
    - 4. Inherited or acquired aplastic anemia;
    - 5. Myelodysplastic syndromes;
  - C. Dietary iron overload;
  - D. Iron overload in liver diseases:
    - 1. Hepatitis C or B;
    - 2. Alcohol-induced liver disease;
    - 3. Porphyria cutanea tarda;
    - 4. Fatty liver disease;
    - 5. Gestational alloimmune liver disease;
  - E. Neonatal iron overload;
  - F. Aceruloplasminemia;
  - G. Repeated heme infusions for acute porphyrias.

### Background

FerriScan<sup>®</sup> is a non-invasive technology based on MRI. It has a high sensitivity and specificity for the measurement of LIC over the entire range encountered in clinical practice. It can be set up on most 1.5 Tesla MRI scanners (the most common type of clinical scanner). FerriScan makes a map of the liver iron concentration and calculates the mean LIC. The results are unaffected by the presence of fibrosis or cirrhosis. Image data is acquired on an MRI scanner and is electronically transmitted to a data analysis center. All data is analyzed to ensure correct acquisition and the LIC results are transmitted back to the originating MRI center.

The operational principle of the R2-MRI Analysis System is based on fitting signal decay curves to the image signal intensities (e.g. of the liver) at the different echo times for the MR data set on a voxel-by-voxel (3-D pixel) basis to determine transverse relaxation rate (R2) images. These may be further transformed by a defined calibration to provide a quantitative measure of liver iron concentrations.

Measurements have been shown to have a high degree of sensitivity and specificity for liver iron concentration measured by biopsy. FerriScan images give information on liver iron distribution. The mean LIC value given in the FerriScan report is then used to guide chelation therapy.

Magnetic resonance evaluation for hepatic iron concentration is improved compared with programs that were used several years ago. However, this type of imaging will not detect cellular liver damage due to iron overload.

The American College of Radiology’s 2020 Practice Parameter for the performance of MRI of the liver states that indications for MRI of the liver include, but are not limited to, evaluation and noninvasive quantification of iron, fat, and fibrosis in chronic liver disease, such as hemochromatosis, hemosiderosis, nonalcoholic steatohepatitis, (NASH) and hepatitis in adults and pediatric patients. Additionally, multiple studies have confirmed the clinical utility of R2 MRI in the measurement of LIC for iron-overloading conditions such as thalassemia<sup>7</sup> and sickle cell anemia<sup>8</sup>. A study of R2 MRI results vs. simulated liver biopsy results found R2 MRI to be superior to liver biopsy for serial LIC observations<sup>9</sup>. Furthermore, a review of the current state of liver iron quantification by MRI states that R2 MRI provides validated measurement of LIC, and has advantages over liver biopsy, in that is in non-invasive.<sup>10</sup>

The R2-MRI Analysis System (Inner Vision Biometrics PTY LTD) received FDA 510(k) clearance (K043271) on January 21, 2005. In January 2013, the FDA authorized the FerriScan R2-MRI to be marketed as an imaging companion diagnostic device for the safe and effective use of Exjade in patients with non-transfusion-dependent thalassemia.

**Coding Implications**

This clinical policy references Current Procedural Terminology (CPT®). CPT® is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2020, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

CPT® Codes	Description
76498	Unlisted MRI procedure

**ICD-10-CM Diagnosis Codes that Support Coverage Criteria**

ICD-10-CM Code	Description
B16.0-B1.9	Acute hepatitis B
B17.10-B17.11	Acute hepatitis C
B18.0	Chronic viral hepatitis B, with delta -agent
B18.1	Chronic viral hepatitis B without delta-agent
B18.2	Chronic viral hepatitis C

**CLINICAL POLICY**  
**Ferriscan R2-MRI**

ICD-10-CM Code	Description
B19.10-B19.11	Unspecified viral hepatitis B
B19.20-B19.21	Unspecified viral hepatitis C
D46.0	Refractory anemia without ring sideroblasts, so stated
D46.1	Refractory anemia with ring sideroblasts
D46.20-D46.22	Refractory anemia with excess of blasts
D56.1	Beta thalasemia
D61.01- D61.9	Other aplastic anemias and other bone marrow failure syndromes
D64.0	Hereditary sideroblastic anemia
D64.1	Secondary sideroblastic anemia due to disease
D64.2	Secondary sideroblastic anemia due to drugs and toxins
D64.3	Other sideroblastic anemia
D64.4	Congenital dyserythropoietic anemia
E80.1	Porphyria cutanea tarda
E83.10	Disorders of iron metabolism, unspecified
E83.110	Hereditary hemochromatosis
E83.111	Hemochromatosis due to repeated red blood cell transfusions
E83.118	Other hemochromatosis
K70.0-K70.9	Alcoholic liver disease
K76.0	Fatty (change of) liver, not elsewhere classified

Reviews, Revisions, and Approvals	Date	Approval Date
Policy developed	11/12	11/12
Changed Ferriscan from not medically necessary to medically necessary in cases of suspected iron overload. Added supporting background information. Added ICD-10 codes. Specialist reviewed.	10/16	11/16
Added "inherited or acquired" to B.4 Aplastic anemia. Added D.5 Gestational alloimmune liver disease, removed "chronic" from D. Iron overload in liver diseases. Removed E. African iron overload because this would be included under C. Dietary iron overload. Added G. Repeated hemin infusions for acute porphyrias.	11/17	11/17
References reviewed and updated. Codes reviewed and updated.	10/18	10/18
Changed "thalassemia major and thalassemia intermedia" to "thalassemia major or thalassemia intermedia." Changed "hepatitis C and B" to "hepatitis C or B"	12/18	
References reviewed and updated. Reviewed by specialist. Replaced codes D61.89 and D61.9 with expanded range of D61.01-D61.9.	10/19	10/19
References reviewed and updated. Replaced "member" with "member/enrollee" in all instances.	09/20	10/20

**References**

1. ACR. Practice Guideline for the Performance of Magnetic Resonance Imaging (MRI) of the Liver. Revised 2020 (Res. 27). Accessed at: <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/MR-Liver.pdf>

2. FerriScan® R2-MRI Fact Sheet. Resonance Health. Revised March 2015. Accessed at: <http://www.resonancehealth.com/images/files/FerriScan/FerriScan%20Fact%20Sheet%20Mar%202015.pdf>
3. Fischer R, Harmatz PR. Non-invasive assessment of tissue iron overload. *Hematology Am Soc Hematol Educ Program*. 2009:215-21
4. Bacon BR, Kwiatkowski JL. Approach to the Patient with Suspected Iron Overload. In: UpToDate, Mentzer WC, Mahoney DH (Eds), UpToDate, Waltham, MA, 2015. Accessed September 28, 2020.
5. Taher A, Musallam KM, El Rassi F, et al. Levels of non-transferrin-bound iron as an index of iron overload in patients with thalassaemia intermedia. *British Journal of Haematology*, 146: 569–572. doi: 10.1111/j.1365-2141.2009.07810.x.
6. Kwiatkowski JL, Kim HY, Thompson AA, et al. Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort. *Blood*. 2012 Mar 22; 119(12): 2746–2753. doi: 10.1182/blood-2011-04-344507
7. Wood JC, Pressel S, Rogers ZR, et al. Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baselines results from the TWITCH trial. *Am J Hematol*. 2015 Sep; 90(9): 806–810. doi: 10.1002/ajh.24089.
8. Wood JC, Zhang P, Rienhoff H, Abi-Saab W, Neufeld EJ. Liver MRI is more precise than liver biopsy for assessing total body iron balance: a comparison of MRI relaxometry with simulated liver biopsy results. *Magn Reson Imaging*. 2015 Jul;33(6):761-7. doi: 10.1016/j.mri.2015.02.016. Epub 2015 Feb 20.
9. Hernando D, Levin YS, Sirlin CB, Reeder SB. Quantification of liver iron with MRI: State of the art and remaining challenges. *J Magn Reson Imaging*. 2014 Nov; 40(5): 1003–1021.
10. Tamary H, Dgany O. Congenital Dyserythropoietic Anemia Type 1. Eds: Pagon RA, Adam MP, Wallace SE, et al. *GeneReviews*® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2016. 2009 Apr 21 [updated 2016 Aug 25].
11. d'Assignies G, Paisant A, Bardou-Jacquet E, et al. Non-invasive measurement of liver iron concentration using 3-Tesla magnetic resonance imaging: validation against biopsy. *Eur Radiol*. 2018 May;28(5):2022-2030. doi: 10.1007/s00330-017-5106-3. Epub 2017 Nov 24.
12. Jhaveri KS, Kannengiesser SAR, Ward R, et al. Prospective Evaluation of an R2\* Method for Assessing Liver Iron Concentration (LIC) Against FerriScan: Derivation of the Calibration Curve and Characterization of the Nature and Source of Uncertainty in the Relationship. *J Magn Reson Imaging*, 2019 May;49(5):1467-1474.
13. Kowdley KV, Brown KE, Ahn J, Sundaram K. ACG Clinical Guideline: Hereditary Hemochromatosis. *Am J Gastroenterol*. 2019 Aug;114(8):1202-1218. doi: 10.14309/ajg.0000000000000315.

### **Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical

## CLINICAL POLICY

### Ferriscan R2-MRI

practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members/enrollees. This clinical policy is not intended to recommend treatment for members/enrollees. Members/enrollees should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members/enrollees and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members/enrollees and their representatives agree to be bound by such terms and conditions by providing services to members/enrollees and/or submitting claims for payment for such services.

**Note: For Medicaid members/enrollees**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

**Note: For Medicare members/enrollees**, to ensure consistency with the Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs, LCDs, and Medicare Coverage Articles should be reviewed prior to applying the criteria

**CLINICAL POLICY**  
**Ferriscan R2-MRI**



set forth in this clinical policy. Refer to the CMS website at <http://www.cms.gov> for additional information.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.